SCHEMBL2146361

SCHEMBL2146361

Cc1noc(C)c1-c1c(/C=N/O)c2ccccc2n1-c1ccc(O)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 6/20 0.38
ALDH1A1 P00352 5/20 0.38
TSHR P16473 4/20 0.38
MAPK1 P28482 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP1A2 P05177 7/20 0.37
CYP2C19 P33261 6/20 0.37
HSD17B10 Q99714 5/20 0.37
LMNA P02545 5/20 0.37
USP2 O75604 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
APEX1 P27695 1/20 0.37
BRD4 O60885 6/20 0.36
CYP3A4 P08684 6/20 0.35
CLK4 Q9HAZ1 4/20 0.35
CYP2C9 P11712 2/20 0.35
ERN1 O75460 2/20 0.35
HIF1A Q16665 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146365 1.00 ALOX15 (0.38) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2146772 0.90 CYP1A2 (0.36) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2146768 0.90 CYP1A2 (0.36) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2290325 0.89 ERN1 (0.43) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2146461 0.88 ERN1 (0.37) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2146466 0.88 ERN1 (0.37) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2147661 0.85 ERN1 (0.40) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2147668 0.85 ERN1 (0.40) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2159526 0.85 CYP1A2 (0.37) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL2159532 0.85 CYP1A2 (0.37) ALOX15ALDH1A1TSHRMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP disclosed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 ALOX15 2595/4885ALDH1A1 1197/4885TSHR 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.